Skip to content
Screener

Mannkind MNKD Liability Sale For Future Royalties Current

Liability Sale For Future Royalties Current at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$305.04M+22.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$76M+19.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$76M+19.0%
Regenxbio logo
RegenxbioRGNX
$42.56M+10.2%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$2.02B+9.3%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$100M0.0%

Other financials

Income statement

See full
Revenue$109.4M+42.9%
Gross profit$95.0M+32.0%
Operating income-$350.0K-107%
Net income-$19.0M-2,949%
EPS (diluted)-$0.06

Balance sheet

See full
Cash & equivalents$52.9M-7.2%
Total debt$11.8M-7.5%
Total equity-$67.2M-22.1%
Total assets$732.3M+77.9%

Cash flow

See full
Operating cash flow-$18.4M-305%
CapEx$5.1M+355%
Free cash flow-$23.5M-399%

Valuation

See full
Market cap$1.25B+17.8%
Enterprise value$1.21B+18.9%
P/S3.2×-0.3×

Profitability

See full
Gross margin89.8%-4.8pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity44.2%
Debt / equity-0.2×
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept mnkd:LiabilitySaleForFutureRoyaltiesCurrent.

The source filing: Mannkind’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335054
Line itemJune 30, 2026December 31, 2025
Accounts payable$11,042$9,034
Accrued expenses and other current liabilities60,76864,628
Senior convertible notes – current36,280
Liability for sale of future royalties – current14,29214,298
Contingent consideration – current34,01521,132
Financing liability – current10,48610,328
Deferred revenue – current11,08515,331
Recognized loss on purchase commitments – current1,210

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Mannkind's liability sale for future royalties current?
Mannkind (MNKD) reported liability sale for future royalties current of $14.29M in Q2 2026.
How has Mannkind's liability sale for future royalties current changed year-over-year?
Mannkind's liability sale for future royalties current increased by 7.1% year-over-year, from $13.34M to $14.29M.
What is the long-term trend for Mannkind's liability sale for future royalties current?
Over 2 years (2023 to 2025), Mannkind's liability sale for future royalties current has grown at a 21.1% compound annual growth rate (CAGR), from $9.76M to $14.3M.
What does liability sale for future royalties current mean?
Liability Sale For Future Royalties Current as reported by Mannkind Corporation.

Ask your AI about Mannkind's liability sale for future royalties current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude